表紙
市場調査レポート

H. Lundbeck A/S:パイプライン製品の分析

H. Lundbeck A/S - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 192615
出版日 ページ情報 英文 59 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
H. Lundbeck A/S:パイプライン製品の分析 H. Lundbeck A/S - Product Pipeline Review - 2016
出版日: 2016年03月22日 ページ情報: 英文 59 Pages
概要

H. Lundbeck A/Sは製薬会社で、うつ病、統合失調症、パーキンソン病、アルツハイマー病、ハンチントン病、てんかん、不眠症など、中枢神経系(CNS)関連の疾患の治療に対する医薬品の研究・開発・製造・販売に従事しています。

当レポートでは、H. Lundbeck A/Sによる治療用パイプライン製品の開発状況について調査分析し、研究・開発の概要、パイプライン製品の概要、治験の段階別の製品の概要、薬剤プロファイル、パイプライン分析、企業情報などを提供して、概略以下の構成でお届けいたします。

目次

H. Lundbeck A/Sの概要

H. Lundbeck A/S - 研究・開発の概要

  • 主要治療分野

H. Lundbeck A/S - パイプライン検証

  • パイプライン製品:開発段階別
  • パイプライン製品 - 単独療法
  • パイプライン製品 - 提携製品
  • パイプライン製品 - アウトライセンス製品

H. Lundbeck A/S - パイプライン製品の概要

  • パイプライン製品 - 後期段階のパイプライン製品
  • パイプライン製品 - 治験段階のパイプライン製品
  • パイプライン製品 - 初期段階のパイプライン製品

H. Lundbeck A/S - 薬剤プロファイル

  • carbamazepine
  • vortioxetine hydrobromide
  • desmoteplase
  • LuAE-58054
  • LuAF-11167
  • tedatioxetine
  • KW-6356
  • LUAF-20513
  • LUAF-64280
  • ホスホジエステラーゼ 10A 阻害薬
  • LRRK-2を阻害する小分子(パーキンソン病)

H. Lundbeck A/S - パイプライン分析

  • パイプライン製品:標的別
  • パイプライン製品:投与経路別
  • パイプライン製品:分子タイプ別
  • パイプライン製品:作用機序別

H. Lundbeck A/S - 最近のパイプライン動向

H. Lundbeck A/S - 休止状態のプロジェクト

H. Lundbeck A/S - 中止されたパイプライン製品

H. Lundbeck A/S - 財務諸表

H. Lundbeck A/S - 所在地と子会社

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08001CDB

Summary

Global Markets Direct's, 'H. Lundbeck A/S - Product Pipeline Review - 2016', provides an overview of the H. Lundbeck A/S's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by H. Lundbeck A/S, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of H. Lundbeck A/S
  • The report provides overview of H. Lundbeck A/S including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses H. Lundbeck A/S's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features H. Lundbeck A/S's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate H. Lundbeck A/S's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for H. Lundbeck A/S
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding H. Lundbeck A/S's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • H. Lundbeck A/S Snapshot
    • H. Lundbeck A/S Overview
    • Key Information
    • Key Facts
  • H. Lundbeck A/S - Research and Development Overview
    • Key Therapeutic Areas
  • H. Lundbeck A/S - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • H. Lundbeck A/S - Pipeline Products Glance
    • H. Lundbeck A/S - Late Stage Pipeline Products
      • Filing rejected/Withdrawn Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • H. Lundbeck A/S - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • H. Lundbeck A/S - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • H. Lundbeck A/S - Drug Profiles
    • carbamazepine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • idalopirdine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LuAF-35700
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nalmefene
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vortioxetine hydrobromide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LuAF-11167
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LUAF-20513
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LUAF-64280
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AF-40431
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize nAChR Alpha-4 Beta-2 for Brain Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit LRRK-2 for Parkinson's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • H. Lundbeck A/S - Pipeline Analysis
    • H. Lundbeck A/S - Pipeline Products by Target
    • H. Lundbeck A/S - Pipeline Products by Route of Administration
    • H. Lundbeck A/S - Pipeline Products by Molecule Type
    • H. Lundbeck A/S - Pipeline Products by Mechanism of Action
  • H. Lundbeck A/S - Recent Pipeline Updates
  • H. Lundbeck A/S - Dormant Projects
  • H. Lundbeck A/S - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • gaboxadol
      • LuAA-47070
      • idalopirdine
      • Lu-02750
      • Lu-35138
      • Lu-AA24493
      • LuAA-37096
      • LuAA-38466
      • LuAA-39959
      • LuAA-44608
      • LuAE-04621
      • ORE-10002
      • siramesine
      • tedatioxetine hydrobromide
      • vortioxetine hydrobromide
      • zicronapine
  • H. Lundbeck A/S - Company Statement
  • H. Lundbeck A/S - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • H. Lundbeck A/S, Key Information
  • H. Lundbeck A/S, Key Facts
  • H. Lundbeck A/S - Pipeline by Indication, 2016
  • H. Lundbeck A/S - Pipeline by Stage of Development, 2016
  • H. Lundbeck A/S - Monotherapy Products in Pipeline, 2016
  • H. Lundbeck A/S - Partnered Products in Pipeline, 2016
  • H. Lundbeck A/S - Partnered Products/ Combination Treatment Modalities, 2016
  • H. Lundbeck A/S - Out-Licensed Products in Pipeline, 2016
  • H. Lundbeck A/S - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • H. Lundbeck A/S - Filing rejected/Withdrawn, 2016
  • H. Lundbeck A/S - Phase III, 2016
  • H. Lundbeck A/S - Phase II, 2016
  • H. Lundbeck A/S - Phase I, 2016
  • H. Lundbeck A/S - Preclinical, 2016
  • H. Lundbeck A/S - Discovery, 2016
  • H. Lundbeck A/S - Pipeline by Target, 2016
  • H. Lundbeck A/S - Pipeline by Route of Administration, 2016
  • H. Lundbeck A/S - Pipeline by Molecule Type, 2016
  • H. Lundbeck A/S - Pipeline Products by Mechanism of Action, 2016
  • H. Lundbeck A/S - Recent Pipeline Updates, 2016
  • H. Lundbeck A/S - Dormant Developmental Projects,2016
  • H. Lundbeck A/S - Discontinued Pipeline Products, 2016
  • H. Lundbeck A/S, Subsidiaries

List of Figures

  • H. Lundbeck A/S - Pipeline by Top 10 Indication, 2016
  • H. Lundbeck A/S - Pipeline by Stage of Development, 2016
  • H. Lundbeck A/S - Monotherapy Products in Pipeline, 2016
  • H. Lundbeck A/S - Partnered Products in Pipeline, 2016
  • H. Lundbeck A/S - Out-Licensed Products in Pipeline, 2016
  • H. Lundbeck A/S - Pipeline by Top 10 Target, 2016
  • H. Lundbeck A/S - Pipeline by Route of Administration, 2016
  • H. Lundbeck A/S - Pipeline by Molecule Type, 2016
  • H. Lundbeck A/S - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top